MT-125 treatment for recurrent high-grade brain tumors
Official title: Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas
Funded at Myosin Therapeutics INC. · NIH-11174970 · Data updated 2026-11-12
Adults with recurrent high-grade gliomas will receive the brain-penetrant drug MT-125 to find safe doses and check whether it can slow tumor invasion and growth.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Myosin Therapeutics INC. NIH-funded |
| Lab location | 1 site (Jupiter, United States) |
| Project start | April 1, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $2,245,802 |
| NIH project number | 2R44CA278293-04 |
| Project ID | NIH-11174970 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with recurrent high-grade gliomas (including glioblastoma) who meet the trial's health and prior-treatment criteria and can travel to the study site would be ideal candidates.
✕Less likely to help
People with low-grade brain tumors, newly diagnosed glioblastoma who have not completed initial standard therapy, serious competing medical conditions, or inability to attend site visits are unlikely to benefit from this trial.
What this research studies
This early-phase dose-escalation trial gives MT-125 alone to adults with recurrent high-grade gliomas to identify the safest and brain-penetrant dose. Participants will have regular clinic visits, blood tests, brain imaging, and possible tumor sampling to track side effects, drug levels in the brain, and signs that tumors stop invading or dividing. Doses are increased carefully in small groups to find dose-limiting toxicities and the recommended dose for future trials, and results will be compared with preclinical data showing MT-125 blocks both invasion and proliferation.
Why it matters
Potential benefit: If successful, MT-125 could slow tumor invasion and growth and potentially extend survival for people with recurrent high-grade gliomas.
How similar studies have gone: Preclinical lab and animal studies show MT-125 can block both invasion and proliferation and extend survival, but this is an early human trial and similar NMII-targeting drugs have not yet been proven effective in patients.
Where this research is happening
-
Myosin Therapeutics INC.
Jupiter, United States Active
Researchers
- Principal investigator: Brownstein, Michael J — Myosin Therapeutics INC.
- Study coordinator: Brownstein, Michael J
Related research
Other NIH-funded projects on the same topics.
-
MT-125: a brain-penetrant treatment to slow glioblastoma spread and growth
A new drug, MT-125, taken by people with recurrent glioblastoma, targets two motor proteins to slow cancer spread and growth inside the brain.
-
How immune myeloid cells affect aggressive childhood brain tumors
Researchers are looking at whether immune cells called macrophages and neutrophils inside and around aggressive childhood brain tumors are linked to tumor behavior and survival in children with high-grade gliomas.
-
Investigating the role of immune cells in childhood brain tumors
This study is looking at how certain immune cells in the brain, called macrophages and neutrophils, affect a type of brain cancer in kids, and it hopes to find new ways to help treat these young patients better.
-
Understanding how a specific histone mutation affects brain tumor development in children
This study is looking at how a specific change in a gene related to brain development might lead to brain tumors in kids, with the hope that understanding this could help find better treatments for these tough-to-treat tumors.
-
Developing mRNA therapies for a deadly pediatric brain tumor
This study is exploring a new way to treat a tough brain tumor called diffuse midline glioma in kids by using special particles to deliver gene therapy directly to the tumor, aiming to improve how we fight this disease.
-
Using oncolytic viruses to deliver genes for treating high-grade gliomas
This study is exploring a new way to treat aggressive brain tumors in kids by using special viruses that can target and destroy cancer cells, while also boosting the body's immune system to help fight the cancer better, and some patients may have the chance to try these exciting new treatments in clinical trials.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.